Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Top tierNeurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering, developing, and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine, and immunological disorders.
In the company’s own words · 10-K filed Feb 11, 2026 · SEC EDGAR
Business segments
Q1 2025 · $15.6MThe company’s own SEC segment disclosure.
- Collaboration$8.9M57%
- Royalty$6.7M43%
Neurocrine Biosciences, Inc. (NBIX) reported revenue of $815M in Q1 2026 (quarter ended Mar 31, 2026), up 42% from the same quarter a year earlier. That came with a gross margin of 98% and net income of $198M (24% of revenue). For the full year FY2025, revenue was $2.86B (+21% year on year) and net income $479M. Its largest product in Q1 2025 (quarter ended Mar 31, 2025) was Collaboration at $8.9M, 57% of the disclosed total, ahead of Royalty at 43%.
Raw charts
10 series · TTMAs reported to the SEC, without any scoring.
Drug Manufacturers - Specialty & Generic
Ranks #1 of 29 by Smart Score